See every side of every news story
Get Started
SubscribeLogin
Basketball
Donald Trump
CPAC
Everton
Pope Francis
Hamas
Ukraine War
Volodymyr Zelenskyy
Baseball
Elon Musk
Israel-Hamas Conflict
Premier League
Published • loading... • Updated

InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China

Summary by Clinical Trials Arena
China's NMPA has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) with orelabrutinib as a first-line therapy for CLL/SLL.The post InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China

China's NMPA has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) with orelabrutinib as a first-line therapy for CLL/SLL.The post InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China appeared first on Clinical Trials Arena.

Read Full Article
pipelinereviewpipelinereview

InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China - Pipelinereview

BEIJING, China I February 17, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the registrational Phase III clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelab…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pipelinereview broke the news in on Monday, February 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

China

China

News
For You
Search
BlindspotLocal